Effect of valproic acid on the outcome of glioblastoma multiforme (Q45231801)

11 December 2017

title

Effect of valproic acid on the outcome of glioblastoma multiforme (English)

1 reference

11 December 2017

1 reference

Hong-Chieh Tsai

1

1 reference

11 December 2017

Kuo-Chen Wei

2

1 reference

11 December 2017

Chi-Neu Tsai

3

1 reference

11 December 2017

Ying-Cheng Huang

4

1 reference

11 December 2017

Pin-Yuan Chen

5

1 reference

11 December 2017

Shu-Mei Chen

6

1 reference

11 December 2017

Yu-Jen Lu

7

1 reference

11 December 2017

Shih-Tseng Lee

8

1 reference

11 December 2017

publication date

15 December 2011

1 reference

British Journal of Neurosurgery

11 December 2017

published in

1 reference

11 December 2017

volume

26

1 reference

11 December 2017

issue

3

1 reference

11 December 2017

page(s)

347-354

1 reference

Adult glioma incidence trends in the United States, 1977-2000.

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Radiotherapy and sequential temozolomide compared with radiotherapy with concomitant and sequential temozolomide in the treatment of newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Survival comparison between glioblastoma multiforme and other incurable cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Histone deacetylase inhibitors as new cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

HDAC inhibitors and ionizing radiation: combinatorial strategy to combat lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Role of histone deacetylases and their inhibitors in cancer biology and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

A Phase II Clinical Trial of Oral Valproic Acid in Patients with Castration-Resistant Prostate Cancers Using an Intensive Biomarker Sampling Strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Valproic acid for the treatment of pediatric malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Valproic acid induces differentiation of a supratentorial primitive neuroectodermal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Valproic acid treatment of glioblastoma multiforme in a child

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Univariate and multivariate statistical analysis of high-grade gliomas: the relationship of radiation dose and other prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Anticonvulsant drugs in primary headaches prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Valproic acid induces polarization, neuronal-like differentiation of a subpopulation of C6 glioma cells and selectively regulates transgene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2011.638996

10.3109/02688697.2011.638996

21 January 2018

Identifiers

DOI

1 reference

11 December 2017

1 reference